Amgen Asks Fed. Circ. To Uphold $70M Hospira IP Verdict
Amgen Inc. has asked the Federal Circuit to preserve a $70 million jury verdict finding that Hospira's biosimilar version of the blockbuster anemia treatment Epogen infringed an Amgen patent, saying Hospira...To view the full article, register now.
Already a subscriber? Click here to view full article